NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.81 +0.79 (+1.01%) GOLD FUTURES
2,392.20 +32.30 (+1.37%) DOW
39,902.88 +344.77 (+0.87%) Bitcoin GBP
52,149.31 +3,555.55 (+7.32%)
Neurocrine Biosciences, Inc. (NBIX)
| Previous close | 138.48 |
| Open | 138.90 |
| Bid | 141.34 x 600 |
| Ask | 141.88 x 700 |
| Day's range | 138.90 - 141.69 |
| 52-week range | 89.04 - 148.37 |
| Volume | |
| Avg. volume | 852,318 |
| Market cap | 14.259B |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | 38.50 |
| EPS (TTM) | 3.68 |
| Earnings date | 30 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 29 Dec 1995 |
| 1y target est | 158.60 |
PR NewswireNeurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Diurnal Ltd., a Neurocrine Biosciences company, presented baseline data from the CAHtalyst™ Phase 3 studies of crinecerfont in adult and pediatric patients with congenital adrenal hyperplasia (CAH), and modified-release hydrocortisone (Chronocort®) data for a Phase 2 clinical study (CHAMPAIN) in participants with primary adrenal insufficiency and in a Phase 3 extension study in CAH. These data, along with several additional posters were presented a
Investor's Business DailyHow Neurocrine Is Stacking Up Wins In 2024 — And Outperforming Peers
Neurocrine Biosciences is making good on its promise to diversify from Ingrezza. Meanwhile, the biotech stock is angling for a record.
- PR Newswire
Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present CAHtalyst™ Adult Phase 3 clinical study baseline characteristics for adults with congenital adrenal hyperplasia (CAH) enrolled in the study, as well as data from a comprehensive literature review assessing the impact of supraphysiologic glucocorticoid (GC) doses on psychiatric disorders and cognition in patients with CAH.
